The Claim
Once-weekly semaglutide 2.4 mg likely reduces the urinary albumin-to-creatinine ratio (UACR) by 10.7% over 104 weeks in adults with overweight or obesity and cardiovascular disease but without diabetes, with a more pronounced reduction of 27.2% in individuals who have baseline albuminuria (UACR ≥30 mg/g), suggesting a beneficial impact on markers of kidney damage.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a weekly semaglutide shot might help protect your kidneys by reducing a marker of kidney damage, especially if you already have early signs of kidney issues.
See the scientific wording
Once-weekly semaglutide 2.4 mg likely reduces urinary albumin-to-creatinine ratio (UACR) by 10.7% at 104 weeks in adults with overweight or obesity, cardiovascular disease, and no diabetes, with a greater reduction of 27.2% observed in those with baseline albuminuria (UACR ≥30 mg/g), indicating a beneficial effect on kidney damage markers.
What the research says
1 studyStudy: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The study looked at a kidney-friendly effect of semaglutide, but it didn’t measure the exact urine test (UACR) that the claim talks about, so we can’t say for sure if those numbers are right.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.